Fate Pharma - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים FATE

Fate Therapeutics, Inc. (FATE) is systematically depleting its accumulated reserves to fund costly therapy trials. This linear chart of year-over-year (TTM) sales growth on GURU.Markets reflects the revenue dynamics, where the indicator value stands at -32.90. High R&D barriers make the company an attractive acquisition target for tech giants, while the demand for cancer treatment ensures business resilience regardless of economic cycles.
Fate Therapeutics (FATE) - פילוחי מדדים ודוחות פיננסיים

Fate Therapeutics, Inc. (FATE) investments in cutting-edge laboratories and an elite staff of biologists must translate into commercial success reflected in the last twelve months (LTM) revenue growth rate. This indicator compares revenues from the past twelve months with the same prior period, allowing for the identification of a divergence between the share price and actual business expansion dynamics to prevent the purchase of an overvalued asset.